19994Miami VA Healthcare System, Miami, FL, USA.
3239Lake Erie College of Osteopathic Medicine, USA.
J Pharm Pract. 2022 Dec;35(6):1039-1043. doi: 10.1177/08971900211008623. Epub 2021 Apr 15.
To describe a potential drug interaction between warfarin and the combination of remdesivir with dexamethasone.
Two male patients, a 71-year-old and 62-year-old presented to the emergency department for symptoms of coronavirus disease 2019 (COVID-19). Both patients were on long-term warfarin therapy with their most recent international normalized ratio (INR) prior to admission within their patient specific goal as managed by their outpatient Pharmacist. In both instances, the patients denied any changes in diet, lifestyle, or missed doses of medications upon admission interview. During admission, both patients experienced a marked elevation in INR within 24 to 48 hours of the initiation of remdesivir with dexamethasone for COVID-19 pneumonia directed therapy. The patients were both eventually stable and were instructed to continue warfarin monitoring and management under the direction of their outpatient Pharmacist upon discharge.
The underrecognized but probable interaction between warfarin in conjunction with remdesivir and dexamethasone warrants further analysis.
描述华法林与瑞德西韦联合地塞米松治疗可能产生的药物相互作用。
两名男性患者,71 岁和 62 岁,因 2019 年冠状病毒病(COVID-19)的症状到急诊科就诊。这两名患者在入院前均长期接受华法林治疗,且他们的 INR 值在前一天均处于其由门诊药师管理的特定患者目标范围内。在这两种情况下,患者在入院访谈时均否认饮食、生活方式有任何改变,也没有漏服药物。入院后,这两名患者在接受瑞德西韦联合地塞米松治疗 COVID-19 肺炎定向治疗的 24 至 48 小时内,INR 均显著升高。最终两名患者情况稳定,并在出院时根据门诊药师的指示继续接受华法林监测和管理。
华法林与瑞德西韦和地塞米松联合使用的潜在相互作用被低估,但很可能存在,需要进一步分析。